Proenkephalin A119-159 As A Biomarker of Acute Kidney Injury in ICU Patients with Sepsis
Ibrahim, M., Badr, M., Abd El-Hassib, D., Mahdey, A. (2022). Proenkephalin A119-159 As A Biomarker of Acute Kidney Injury in ICU Patients with Sepsis. EKB Journal Management System, 89(1), 4197-4204. doi: 10.21608/ejhm.2022.256323
Mohamed E. Ibrahim; Mohamed Ibrahim Mohamed Badr; Dalia Mohamed Abd El-Hassib; Ahmed Wageh Mahdey. "Proenkephalin A119-159 As A Biomarker of Acute Kidney Injury in ICU Patients with Sepsis". EKB Journal Management System, 89, 1, 2022, 4197-4204. doi: 10.21608/ejhm.2022.256323
Ibrahim, M., Badr, M., Abd El-Hassib, D., Mahdey, A. (2022). 'Proenkephalin A119-159 As A Biomarker of Acute Kidney Injury in ICU Patients with Sepsis', EKB Journal Management System, 89(1), pp. 4197-4204. doi: 10.21608/ejhm.2022.256323
Ibrahim, M., Badr, M., Abd El-Hassib, D., Mahdey, A. Proenkephalin A119-159 As A Biomarker of Acute Kidney Injury in ICU Patients with Sepsis. EKB Journal Management System, 2022; 89(1): 4197-4204. doi: 10.21608/ejhm.2022.256323

Proenkephalin A119-159 As A Biomarker of Acute Kidney Injury in ICU Patients with Sepsis

The Egyptian Journal of Hospital Medicine
Article 9, Volume 89, Issue 1, October 2022, Page 4197-4204  XML PDF (764.46 K)
Document Type: Original Article
DOI: 10.21608/ejhm.2022.256323
View on SCiNiTO View on SCiNiTO
Authors
Mohamed E. Ibrahim; Mohamed Ibrahim Mohamed Badr email ; Dalia Mohamed Abd El-Hassib; Ahmed Wageh Mahdey
Abstract
Background: Sepsis is a potentially fatal illness caused by an unbalanced host response to infection. Sepsis is becoming more common, indicating that it is a main cause of severe disease and fatality globally. Patients with sepsis commonly have simultaneous acute kidney injury (AKI), with rates ranging from 5 to 20% among hospital admissions and increasing to 35-50% among the seriously sick. Because proenkephalin is not bound to proteins in plasma and is only filtrated in the glomerulus, it is a promising biomarker for renal impairment in critically sick patients. Objective: The aim of the current study was to assess Proenkephalin A119-159 (penKid) as a biomarker for sepsis related AKI in ICU patients. Patients and methods: A case control study was conducted at intensive care unit (ICU) department, Benha Faculty of Medicine on a total of 80 subjects which were divided into 50 septic AKI cases and 30 matched age and sex controls. Subjects met two or more SIRS-criteria and their estimated glomerular filtration rate (eGFR) was determined by the formula derived from the Modification of Diet in Renal Disease (MDRD) Study and the Proenkephalin A119-159 (penkid) was measured by ELISA. Results: The current study demonstrated that, septic AKI cases demonstrated significant increase in penkid compared to control group(p < strong><0.001) and Penkid level showed significantly positive correlation with baseline, after 48 h creatinine, CRP, SIRS and SOFA scores. Penkid was better than creatinine, eGFR and CRP for prediction of non-recovery septic AKI. Conclusion: PenKid was demonstrated to be a reliable surrogate promising biomarker for sepsis related AKI among unselected patients with sepsis. Additionally, penkid demonstrated superior advantage over creatinine, eGFR and CRP in terms of non-recovery septic AKI prediction.
 
Keywords
Sepsis; Systemic Inflammatory Response Syndrome; Proenkephalin; acute kidney injury; Benha University
Statistics
Article View: 331
PDF Download: 349